Small Lymphocytic Lymphoma Clinical Trials

38 studies are recruiting for small lymphocytic lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Boston, Massachusetts 10 Columbus, Ohio 9 Nashville, Tennessee 9 Houston, Texas 7 New York, New York 7 Seattle, Washington 7 Bethesda, Maryland 6 Chapel Hill, North Carolina 6 Cincinnati, Ohio 6 Palo Alto, California 6 Baton Rouge, Louisiana 5 Chicago, Illinois 5 Rochester, Minnesota 5 Waukee, Iowa 5 Aurora, Colorado 4 Baltimore, Maryland 4 Charlotte, North Carolina 4 Duarte, California 4 Durham, North Carolina 4 Irvine, California 4 Jacksonville, Florida 4 Miami, Florida 4 Milwaukee, Wisconsin 4 Minneapolis, Minnesota 4 Philadelphia, Pennsylvania 4 Phoenix, Arizona 4 Pittsburgh, Pennsylvania 4 Portland, Oregon 4 Richmond, Virginia 4 Billings, Montana 3 Birmingham, Alabama 3 Chattanooga, Tennessee 3 Dallas, Texas 3 Denver, Colorado 3 Detroit, Michigan 3 Eugene, Oregon 3 Fort Wayne, Indiana 3 Grand Rapids, Michigan 3 Hackensack, New Jersey 3 Iowa City, Iowa 3 Kansas City, Missouri 3 La Jolla, California 3 Los Angeles, California 3 Louisville, Kentucky 3 New Orleans, Louisiana 3 Newnan, Georgia 3 Orange, California 3 Salt Lake City, Utah 3 San Francisco, California 3 Spokane, Washington 3 Tampa, Florida 3 Tyler, Texas 3 Winston-Salem, North Carolina 3 York, Pennsylvania 3

Studies, page 2

  1. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage
    Phase 1
    Ages
    13 and older
    Site
    University of Chicago, Chicago, Illinois
    Locations
    8 in total
    Run by
    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov

  2. Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

    This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect against bacteria that cause pneumococcal disease. Giving these va…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT05183854 on ClinicalTrials.gov

  3. Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

    This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Locations
    7 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT07218510 on ClinicalTrials.gov

  4. Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

    This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block the activation of certain cells that lead to the g…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Ohio State University Comprehensive Cancer Center

    See if you can join NCT05336812 on ClinicalTrials.gov

  5. Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

    This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine kinase inhibitors (BTKi). Pirtobrutinib is in a …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Kerry Rogers

    See if you can join NCT06466122 on ClinicalTrials.gov

  6. Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

    This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    New England Cancer Specialists, Scarborough, Maine
    Locations
    4 in total
    Run by
    Inhye Ahn

    See if you can join NCT06333262 on ClinicalTrials.gov

  7. Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

    This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vac…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Seema Bhat

    See if you can join NCT05417165 on ClinicalTrials.gov

  8. Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

    This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Cincinnati, Cincinnati, Ohio
    Run by
    Zulfa Omer

    See if you can join NCT07014917 on ClinicalTrials.gov

  9. Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

    This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Cincinnati, Cincinnati, Ohio
    Run by
    Zulfa Omer

    See if you can join NCT07108998 on ClinicalTrials.gov

  10. Mosunetuzumab for CLL MRD Clearance

    The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of th…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Brigham & Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Inhye Ahn

    See if you can join NCT07052695 on ClinicalTrials.gov

  11. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UC Irvine Health, Orange, California
    Locations
    13 in total
    Run by
    Carna Biosciences, Inc.

    See if you can join NCT05602363 on ClinicalTrials.gov

  12. Two Step Haplo With Radiation Conditioning

    This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania
    Run by
    Thomas Jefferson University

    See if you can join NCT05031897 on ClinicalTrials.gov

  13. LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

    Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Cincinnati Medical Center, Cincinnati, Ohio
    Run by
    Zulfa Omer

    See if you can join NCT06978088 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.